High Growth Tech Stocks In Australia For September 2024

In This Article:

Over the last 7 days, the Australian market has dropped 1.3%, yet it remains up 10% over the past year with earnings forecasted to grow by 12% annually. In this context, identifying high growth tech stocks involves looking for companies that demonstrate robust financial health and strong potential for future expansion despite short-term market fluctuations.

Top 10 High Growth Tech Companies In Australia

Name

Revenue Growth

Earnings Growth

Growth Rating

Clinuvel Pharmaceuticals

22.41%

27.42%

★★★★★★

Pureprofile

14.94%

80.73%

★★★★★☆

AVA Risk Group

32.56%

118.83%

★★★★★★

ImExHS

20.47%

111.20%

★★★★★★

DUG Technology

10.90%

32.21%

★★★★★☆

Pointerra

56.62%

126.45%

★★★★★★

Careteq

34.13%

126.60%

★★★★★☆

Wrkr

36.31%

100.29%

★★★★★★

Adveritas

57.98%

144.21%

★★★★★★

SiteMinder

19.39%

60.31%

★★★★★☆

Click here to see the full list of 62 stocks from our ASX High Growth Tech and AI Stocks screener.

Here's a peek at a few of the choices from the screener.

Pro Medicus

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Pro Medicus Limited is a healthcare informatics company that develops and supplies imaging software and radiology information system (RIS) software and services to hospitals, imaging centers, and healthcare groups in Australia, North America, and Europe, with a market cap of A$16.59 billion.

Operations: Pro Medicus generates revenue primarily from the production of integrated software applications for the healthcare industry, amounting to A$161.50 million. The company operates across Australia, North America, and Europe, focusing on imaging software and radiology information systems (RIS).

Pro Medicus has demonstrated robust financial performance, with revenue rising to AUD 166.33 million and net income reaching AUD 82.79 million for the fiscal year ending June 30, 2024. The company's earnings growth of 36.5% significantly outpaced the Healthcare Services industry average of 13.9%. With an annual profit growth forecasted at 18.7%, Pro Medicus is positioned to continue its upward trajectory, particularly through its innovative medical imaging software solutions that cater to major healthcare providers globally. Investing heavily in R&D, Pro Medicus spent a notable portion of its revenue on innovation, ensuring cutting-edge technology development that supports future growth prospects in the AI-driven healthcare sector. The company’s recent dividend increase by 33.3% also reflects strong financial health and commitment to shareholder returns, enhancing investor confidence in sustained profitability and market expansion potential within Australia’s tech landscape.